rs6490121

This study investigates how the NOS1 variant rs6490121, previously associated with schizophrenia and cognitive function, influences visual sensory processing. In 54 healthy participants, carriers of the risk 'G' allele showed significantly reduced P1 visual evoked potential responses compared to non-carriers. The authors found that NOS1's effect on P1 amplitude was independent of its effects on spatial working memory performance, suggesting the gene exerts pleiotropic effects on both sensory and cognitive processing.

This comprehensive review examines the genomics of schizophrenia and pharmacogenomics of antipsychotic drugs, synthesizing evidence on over 200 genes associated with psychotic disorders. The authors discuss five categories of genes relevant to antipsychotic response: disease-associated genes, mechanism-of-action genes, drug metabolism genes (particularly CYP2D6, CYP2C19, CYP2C9, CYP3A4), drug transporter genes, and pleiotropic genes. The review details pharmacogenomic profiles of 20+ antipsychotic drugs and demonstrates significant ethnic and interindividual variation in drug metabolism phenotypes, with examples including CYP2D6 extensive metabolizers (55.71% of population), intermediate metabolizers (34.7%), poor metabolizers (2.28%), and ultra-rapid metabolizers (7.31%).

This replication study evaluated six GWAS-identified schizophrenia risk loci in a German population of 2,154 individuals (937 with schizophrenia, 632 with bipolar disorder, 585 controls). Despite the original UK GWAS showing strong association with rs1344706 in ZNF804A (P = 1.61 × 10⁻⁷), none of the six GWAS risk alleles were significantly associated with psychosis in the German population. Notably, rs1344706 showed consistently negative results with OR = 1.08 (0.93-1.26 95% CI) for schizophrenia.

This comprehensive review synthesizes genomic and pharmacogenomic research in schizophrenia, discussing over 200 candidate genes associated with psychotic disorders, genetic mechanisms including copy number variants and microRNA alterations, and pharmacogenomic factors affecting antipsychotic efficacy and safety. Key genes covered include dopamine receptors (DRD1-5), dysbindin (DTNBP1), DISC1, neurotrophic factors, and metabolic enzymes such as CYP2D6, CYP3A4, and COMT, with emphasis on genotype-phenotype correlations in antipsychotic response and side effects.